{"id":"https://openalex.org/W2589343447","doi":"https://doi.org/10.1200/jco.2005.23.16_suppl.2560","title":"Molecular targeting of prostate cancer with cytotoxins and radioisotopes linked to fully human monoclonal antibodies against prostate-specific membrane antigen","display_name":"Molecular targeting of prostate cancer with cytotoxins and radioisotopes linked to fully human monoclonal antibodies against prostate-specific membrane antigen","publication_year":2005,"publication_date":"2005-06-01","ids":{"openalex":"https://openalex.org/W2589343447","doi":"https://doi.org/10.1200/jco.2005.23.16_suppl.2560","mag":"2589343447"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2005.23.16_suppl.2560","doi":"https://doi.org/10.1200/jco.2005.23.16_suppl.2560","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2005.23.16_suppl.2560","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5005399548","display_name":"Dangshe Ma","orcid":"https://orcid.org/0000-0002-5919-6402","observed_orcids":["https://orcid.org/0000-0002-5919-6402"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"D. Ma","raw_affiliation_strings":["PSMA Development Company, LLC, Tarrytown, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"PSMA Development Company, LLC, Tarrytown, NY","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5052265847","display_name":"Christine E. Hopf","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"C. E. Hopf","raw_affiliation_strings":["PSMA Development Company, LLC, Tarrytown, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"PSMA Development Company, LLC, Tarrytown, NY","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5049617943","display_name":"Andrew D. Malewicz","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"A. D. Malewicz","raw_affiliation_strings":["PSMA Development Company, LLC, Tarrytown, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"PSMA Development Company, LLC, Tarrytown, NY","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110474870","display_name":"D. Fisch","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"D. Fisch","raw_affiliation_strings":["PSMA Development Company, LLC, Tarrytown, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"PSMA Development Company, LLC, Tarrytown, NY","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5053265522","display_name":"Jason P. Gardner","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"J. P. Gardner","raw_affiliation_strings":["PSMA Development Company, LLC, Tarrytown, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"PSMA Development Company, LLC, Tarrytown, NY","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5064911964","display_name":"Gerald P. Donovan","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"G. P. Donovan","raw_affiliation_strings":["PSMA Development Company, LLC, Tarrytown, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"PSMA Development Company, LLC, Tarrytown, NY","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5068966647","display_name":"Norbert Sch\u00fclke","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"N. Sch\u00fclke","raw_affiliation_strings":["PSMA Development Company, LLC, Tarrytown, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"PSMA Development Company, LLC, Tarrytown, NY","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5036854462","display_name":"William F. Goeckeler","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"W. F. Goeckeler","raw_affiliation_strings":["PSMA Development Company, LLC, Tarrytown, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"PSMA Development Company, LLC, Tarrytown, NY","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5035255731","display_name":"Paul Jay Maddon","orcid":"https://orcid.org/0000-0002-2264-6270","observed_orcids":["https://orcid.org/0000-0002-2264-6270"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"P. J. Maddon","raw_affiliation_strings":["PSMA Development Company, LLC, Tarrytown, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"PSMA Development Company, LLC, Tarrytown, NY","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5017367178","display_name":"William C. Olson","orcid":"https://orcid.org/0000-0001-6254-0641","observed_orcids":["https://orcid.org/0000-0001-6254-0641"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"W. C. Olson","raw_affiliation_strings":["PSMA Development Company, LLC, Tarrytown, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"PSMA Development Company, LLC, Tarrytown, NY","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"23","issue":"16_suppl","first_page":"2560","last_page":"2560"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11395","display_name":"Radiopharmaceutical Chemistry and Applications","score":0.9785000085830688,"subfield":{"id":"https://openalex.org/subfields/2741","display_name":"Radiology, Nuclear Medicine and Imaging"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11395","display_name":"Radiopharmaceutical Chemistry and Applications","score":0.9785000085830688,"subfield":{"id":"https://openalex.org/subfields/2741","display_name":"Radiology, Nuclear Medicine and Imaging"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.007300000172108412,"subfield":{"id":"https://openalex.org/subfields/2741","display_name":"Radiology, Nuclear Medicine and Imaging"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12477","display_name":"Toxin Mechanisms and Immunotoxins","score":0.006500000134110451,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/prostate-cancer","display_name":"prostate cancer","score":0.8650000095367432},{"id":"https://openalex.org/keywords/immunotoxins","display_name":"immunotoxins","score":0.8119999766349792},{"id":"https://openalex.org/keywords/radiolabeled-antibodies","display_name":"radiolabeled antibodies","score":0.8790000081062317},{"id":"https://openalex.org/keywords/lutetium-177","display_name":"lutetium-177","score":0.9750000238418579},{"id":"https://openalex.org/keywords/targeted-radioimmunotherapy","display_name":"targeted radioimmunotherapy","score":0.7519999742507935},{"id":"https://openalex.org/keywords/antibody-conjugation","display_name":"antibody conjugation","score":0.8090000152587891},{"id":"https://openalex.org/keywords/antibody-internalization","display_name":"antibody internalization","score":0.7689999938011169},{"id":"https://openalex.org/keywords/tumor-targeting","display_name":"tumor targeting","score":0.6159999966621399},{"id":"https://openalex.org/keywords/xenograft-models","display_name":"xenograft models","score":0.6510000228881836},{"id":"https://openalex.org/keywords/cytotoxicity","display_name":"cytotoxicity","score":0.531000018119812}],"concepts":[{"id":"https://openalex.org/C542903549","wikidata":"https://www.wikidata.org/wiki/Q422248","display_name":"Monoclonal antibody","level":3,"score":0.7674586772918701},{"id":"https://openalex.org/C115085202","wikidata":"https://www.wikidata.org/wiki/Q425665","display_name":"Immunotoxin","level":4,"score":0.7487084269523621},{"id":"https://openalex.org/C109316439","wikidata":"https://www.wikidata.org/wiki/Q246181","display_name":"Cytotoxicity","level":3,"score":0.647822380065918},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.6309632062911987},{"id":"https://openalex.org/C2780192828","wikidata":"https://www.wikidata.org/wiki/Q181257","display_name":"Prostate cancer","level":3,"score":0.6114476919174194},{"id":"https://openalex.org/C195616568","wikidata":"https://www.wikidata.org/wiki/Q128711","display_name":"Epitope","level":3,"score":0.6087226271629333},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.5256054401397705},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.5244688987731934},{"id":"https://openalex.org/C147483822","wikidata":"https://www.wikidata.org/wiki/Q103537","display_name":"Antigen","level":2,"score":0.5126992464065552},{"id":"https://openalex.org/C207001950","wikidata":"https://www.wikidata.org/wiki/Q141124","display_name":"In vivo","level":2,"score":0.46353697776794434},{"id":"https://openalex.org/C20417620","wikidata":"https://www.wikidata.org/wiki/Q4140229","display_name":"Glutamate carboxypeptidase II","level":4,"score":0.4579329788684845},{"id":"https://openalex.org/C154317977","wikidata":"https://www.wikidata.org/wiki/Q376266","display_name":"Cytotoxic T cell","level":3,"score":0.4305551052093506},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.38641178607940674},{"id":"https://openalex.org/C153911025","wikidata":"https://www.wikidata.org/wiki/Q7202","display_name":"Molecular biology","level":1,"score":0.3823414146900177},{"id":"https://openalex.org/C202751555","wikidata":"https://www.wikidata.org/wiki/Q221681","display_name":"In vitro","level":2,"score":0.3741605281829834},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.36284661293029785},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.28054940700531006},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.24007830023765564},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.21884199976921082},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.1336871087551117},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.09160807728767395},{"id":"https://openalex.org/C150903083","wikidata":"https://www.wikidata.org/wiki/Q7108","display_name":"Biotechnology","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2005.23.16_suppl.2560","doi":"https://doi.org/10.1200/jco.2005.23.16_suppl.2560","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2005.23.16_suppl.2560","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.98580002784729}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2281786924","https://openalex.org/W1989481955","https://openalex.org/W3164452959","https://openalex.org/W2083755386","https://openalex.org/W2241372383","https://openalex.org/W2139964684","https://openalex.org/W2048969190","https://openalex.org/W1970545446","https://openalex.org/W1983760836","https://openalex.org/W2781357770"],"abstract_inverted_index":{"2560":[0],"Background:":[1],"Prostate-specific":[2],"membrane":[3],"antigen":[4],"(PSMA)":[5],"is":[6],"an":[7,234],"attractive":[8],"target":[9],"for":[10,151],"immunotherapy":[11],"of":[12,32,40,66,77,84,107,160,192,225,231,246],"prostate":[13,21,53,277,294],"cancer":[14,22,54,278],"due":[15],"to":[16,36,47,52,163,179,262,292],"its":[17,25],"abundant":[18],"expression":[19],"on":[20,27,139,181],"cells":[23,55,183,198],"and":[24,58,68,97,110,121,202,254,299],"up-regulation":[26],"metastatic":[28],"disease.":[29],"The":[30,144,158,171],"objectives":[31],"this":[33,102],"study":[34],"were":[35,146,174],"evaluate":[37],"the":[38,69,104,161,274],"ability":[39],"fully":[41,78,131],"human":[42,79,132,276,284],"anti-PSMA":[43,94],"monoclonal":[44],"antibodies":[45,86],"(mAbs)":[46],"specifically":[48,134],"deliver":[49,289],"cytotoxic":[50,290],"payloads":[51,291],"in":[56,59,115,117,122,185,297,300],"vitro":[57,118,298],"vivo.":[60,301],"Methods:":[61],"Using":[62],"novel":[63],"recombinant":[64],"forms":[65],"PSMA":[67,140,165,180,285,320],"XenoMouse\u2122":[70],"technology,":[71],"we":[72],"previously":[73],"generated":[74],"a":[75,213,221,241],"panel":[76],"mAbs":[80,109,133,145,162,173,209,286],"against":[81],"PSMA.":[82],"Characterization":[83],"these":[85,130],"was":[87,112,166],"conducted":[88],"using":[89,238,273],"Biacore,":[90],"ELISA,":[91],"flow":[92],"cytometry,":[93],"Western":[95],"blot":[96],"other":[98],"functional":[99],"assays.":[100],"In":[101,205,233],"study,":[103],"therapeutic":[105],"potential":[106],"radiolabeled":[108,210],"immunotoxins":[111],"comparatively":[113],"evaluated":[114],"cell-based":[116],"cytotoxicity":[119],"assays":[120],"vivo":[123],"xenografted":[124],"animals.":[125],"Results:":[126],"We":[127],"demonstrated":[128],"that":[129],"recognize":[135],"conformational,":[136],"dimer-specific":[137],"epitopes":[138],"with":[141,148,155,199,211,220],"subnanomolar":[142],"affinity.":[143],"modified":[147],"bifunctional":[149],"chelates":[150],"radiolabeling":[152],"or":[153,305,308],"conjugated":[154,172],"potent":[156],"cytotoxins.":[157,193],"binding":[159,178],"cell-surface":[164],"virtually":[167],"unchanged":[168],"following":[169],"conjugation.":[170],"internalized":[175],"rapidly":[176],"upon":[177],"tumor":[182,197,223,236,252,295],"(\u223c60%":[184],"2":[186],"hours)":[187],"which":[188],"provides":[189],"efficient":[190],"delivery":[191],"Immunotoxins":[194],"killed":[195],"PSMA-expressing":[196,218],"pM":[200],"potency":[201],"\u223c1000-fold":[203],"selectivity.":[204],"tumor-bearing":[206],"animal":[207],"models,":[208],"Lu-177,":[212],"beta-emitting":[214],"isotope,":[215],"selectively":[216,288],"targeted":[217],"tumors,":[219],"high":[222],"uptake":[224],"30%":[226],"injected":[227],"dose":[228,245],"per":[229],"gram":[230],"tumor.":[232],"aggressive":[235],"model":[237],"3T3-PSMA":[239],"cells,":[240],"single":[242],"400":[243],"\u03bcCi":[244],"Lu-177":[247],"labeled":[248],"antibody":[249],"significantly":[250],"delayed":[251],"growth":[253,296],"increased":[255],"median":[256],"survival":[257],"time":[258],"by":[259],"3.5-fold":[260],"compared":[261],"untreated":[263],"control":[264,293],"animals":[265],"(p<0.005).":[266],"Additional":[267],"xenograft":[268],"studies":[269],"have":[270],"been":[271],"initiated":[272],"androgen-independent":[275],"cell":[279],"line":[280],"C4-2.":[281],"Conclusions:":[282],"Fully":[283],"can":[287],"Author":[302],"Disclosure":[303],"Employment":[304],"Leadership":[306],"Consultant":[307],"Advisory":[309],"Role":[310],"Stock":[311],"Ownership":[312],"Honoraria":[313],"Research":[314],"Funding":[315],"Expert":[316],"Testimony":[317],"Other":[318],"Remuneration":[319],"Development":[321],"Company,":[322],"LLC":[323]},"counts_by_year":[],"updated_date":"2026-10-17T09:40:24.721904","created_date":"2017-03-03T00:00:00"}